Galunisertib During Normothermic Machine Perfusion Attenuates Profibrotic Signaling in Discarded Human Donor Kidneys
INTRODUCTION: Early-onset fibrosis limits kidney transplant success, causing early allograft failure in up to 50% of deceased donor kidneys within 10 years or excluding many from transplantation. Normothermic machine perfusion (NMP) offers a platform for targeted drug delivery to isolated organs, minimizing systemic effects. This study evaluated whether galunisertib modulates fibrosis-associated molecular signaling when administered to discarded human kidneys during ex vivo NMP, while assessing treatment safety and pharmacokinetics. METHODS: Twelve discarded human kidneys underwent 4 h of oxygenated hypothermic perfusion followed by 6 h of NMP with galunisertib or vehicle (n = 6). Precision-cut kidney slices (PCKS) were then cultured for 48 h with either continued or discontinued galunisertib exposure. Endpoints included fibrosis-related mRNA expression and pharmacokinetics. RESULTS: Galunisertib was administered during NMP and steadily excreted in urine without adverse effects on organ function. Continued exposure in PCKS significantly attenuated fibrosis-related mRNA expression, including SERPINE1 (24 h: p = 0.0057; 48 h: p = 0.0046). Discontinuation increased ACTA2 expression (p = 0.0156), while continued treatment prevented this phenomenon (p = 0.0014). CONCLUSION: NMP enabled targeted delivery of galunisertib to discarded human kidneys without detectable adverse effects on ex vivo renal function. Prolonged galunisertib exposure was associated with modest attenuation of fibrosis-associated molecular markers during subsequent tissue culture. These findings provide proof-of-concept for pharmacological modulation of profibrotic signaling during ex vivo kidney perfusion.
Authors
- Henri G. D. Leuvenink (ORCID: https://orcid.org/0000-0001-5036-2999)
- Daan Johannes Touw (ORCID: https://orcid.org/0000-0002-1429-4789)
- Petra J. Ottens (ORCID: https://orcid.org/0000-0001-6782-4854)
- Cyril Moers (ORCID: https://orcid.org/0000-0001-8014-8387)
- Peter Olinga (ORCID: https://orcid.org/0000-0003-4855-8452)
- Baran Ogurlu (ORCID: https://orcid.org/0000-0001-5658-6838)
- Christopher L. Jaynes (ORCID: https://orcid.org/0000-0001-8214-2288)
- Veerle A. Lantinga (ORCID: https://orcid.org/0000-0002-6931-2825)
- Carolina Campos Pamplona (ORCID: https://orcid.org/0000-0002-0740-6391)
- Tim L. Hamelink (ORCID: https://orcid.org/0000-0003-4860-5984)
- L. Leonie van Leeuwen (ORCID: https://orcid.org/0000-0003-4666-2993)
- Kai van Hateren
- Jan‐Luuk Hillebrands (ORCID: https://orcid.org/0000-0003-3135-3274)
- Cristina Ballester Bergada (ORCID: https://orcid.org/0009-0005-5827-4156)
Institutions
- Mount Sinai Hospital (US)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Aarhus University Hospital (DK)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Artificial Organs
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1111/aor.70281
- Primary Topic
- Organ Transplantation Techniques and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00